1. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

    Annals of Oncology 27(3):379 (2016) PMID 26681681

    Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss (CTIBL) and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do not currently ha...
  2. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

    Annals of Oncology 26(12):2442 (2015) PMID 26387144 PMCID PMC4658543

    We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy wit...
  3. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

    Annals of Oncology 26(12):2505 (2015) PMID 26467471

  4. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

    The Lancet 386(10001):1341 (2015) PMID 26211827

    The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain. We undertook meta-analyses of individual data on 31,920 postmenopausal women with oestrogen-receptor-positive early breast cancer in the randomised trials of 5 years of a...
  5. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

    Annals of Oncology 26(8):1533 (2015) PMID 25939896 PMCID PMC4511219

    The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitti...
  6. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

    Annals of Oncology 26(5):873 (2015) PMID 25725046

    Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimat...
  7. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.

    Breast Cancer Research and Treatment 143(1):159 (2014) PMID 24305979 PMCID PMC3913479

    There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of...
  8. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

    Annals of Oncology 24(9):2206 (2013) PMID 23917950 PMCID PMC3755334

    The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refi...
  9. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

    Annals of Oncology 24(5):1203 (2013) PMID 23293111

    Background In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease...
  10. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study.

    Journal of Geriatric Oncology 4(1):39 (2013) PMID 24071491

    The primary objective of this population-based study is to describe the patterns of care of elderly patients with breast cancer (BC), and evaluate potential causative factors for the decrease in BC-specific survival (BCSS) in the elderly. We included all or representative samples of patients wit...
  11. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

    Annals of Oncology 23(11):2843 (2012) PMID 22707751 PMCID PMC3477879

    To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosi...
  12. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.

    Annals of Oncology 23(11):2852 (2012) PMID 22776708 PMCID PMC3477880

    Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and target for postmastectomy radiotherapy (PMRT). Local, axillary and supraclavicular recurrences were evaluated in 8106 patients enrolled in 13 randomized trials. Patients received chemotherap...
  13. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).

    Annals of Oncology 23(6):1474 (2012) PMID 22003243

    The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T f...
  14. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

    British Journal of Cancer 106(10):1618 (2012) PMID 22531635 PMCID PMC3349183

    In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). One hundred postmenopausal women, randomised to receive 5 years of adj...
  15. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

    Annals of Oncology 22(10):2201 (2011) PMID 21335417 PMCID PMC3179413

    On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which arom...
  16. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer.

    Journal of Oncology Pharmacy Practice 17(3):292 (2011) PMID 20667851

    We report a case of bevacizumab-associated hyperlipoproteinemia in a patient with advanced breast cancer. A 57-year-old woman with advanced invasive-ductal breast cancer was administered bevacizumab from March 2008 to February 2009. Pretreatment laboratory showed borderline hypercholesterolemia ...
  17. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

    Annals of Oncology 22(8):1736 (2011) PMID 21709140 PMCID PMC3144634

    The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may ...
  18. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.

    Cancer Chemotherapy and Pharmacology 67(5):1137 (2011) PMID 20683595

    There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone-targeted therapies is moderate. We assessed the predictive value of the bone formation marker procollagen type I N-propeptide (PINP) for skeletal morbidity in patients with MBD...
  19. Predictors of state-of-the-art management of early breast cancer in Switzerland.

    Annals of Oncology 22(3):618 (2011) PMID 20705910

    The aim of this study was to investigate predictors of state-of-the-art management of early breast cancer in Switzerland. The study included 3499 women aged 25-79 years diagnosed with invasive breast cancer stages I-IIIA in 2003-2005. Patients were identified through population-based cancer regi...
  20. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?

    Annals of Oncology 22(1):17 (2011) PMID 20566473

    Adjuvant treatment of early-stage breast cancer with combined trastuzumab and chemotherapy has become standard in patients with HER2-positive tumors and a diameter of >1 cm or positive lymph nodes. Currently, there are no data directly supporting the use of adjuvant treatment, including trastuzu...